Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

2XCO

The 3.1A crystal structure of the catalytic core (B'A' region) of Staphylococcus aureus DNA Gyrase

Summary for 2XCO
Entry DOI10.2210/pdb2xco/pdb
Related2XCQ 2XCR 2XCS 2XCT
DescriptorDNA GYRASE SUBUNIT B, DNA GYRASE SUBUNIT A, CALCIUM ION (3 entities in total)
Functional Keywordsisomerase
Biological sourceSTAPHYLOCOCCUS AUREUS
Cellular locationCytoplasm (Potential): Q99XG5
Total number of polymer chains1
Total formula weight82384.98
Authors
Primary citationBax, B.D.,Chan, P.F.,Eggleston, D.S.,Fosberry, A.,Gentry, D.R.,Gorrec, F.,Giordano, I.,Hann, M.M.,Hennessy, A.,Hibbs, M.,Huang, J.,Jones, E.,Jones, J.,Brown, K.K.,Lewis, C.J.,May, E.W.,Saunders, M.R.,Singh, O.,Spitzfaden, C.,Shen, C.,Shillings, A.,Theobald, A.F.,Wohlkonig, A.,Pearson, N.D.,Gwynn, M.N.
Type Iia Topoisomerase Inhibition by a New Class of Antibacterial Agents.
Nature, 466:935-, 2010
Cited by
PubMed Abstract: Despite the success of genomics in identifying new essential bacterial genes, there is a lack of sustainable leads in antibacterial drug discovery to address increasing multidrug resistance. Type IIA topoisomerases cleave and religate DNA to regulate DNA topology and are a major class of antibacterial and anticancer drug targets, yet there is no well developed structural basis for understanding drug action. Here we report the 2.1 A crystal structure of a potent, new class, broad-spectrum antibacterial agent in complex with Staphylococcus aureus DNA gyrase and DNA, showing a new mode of inhibition that circumvents fluoroquinolone resistance in this clinically important drug target. The inhibitor 'bridges' the DNA and a transient non-catalytic pocket on the two-fold axis at the GyrA dimer interface, and is close to the active sites and fluoroquinolone binding sites. In the inhibitor complex the active site seems poised to cleave the DNA, with a single metal ion observed between the TOPRIM (topoisomerase/primase) domain and the scissile phosphate. This work provides new insights into the mechanism of topoisomerase action and a platform for structure-based drug design of a new class of antibacterial agents against a clinically proven, but conformationally flexible, enzyme class.
PubMed: 20686482
DOI: 10.1038/NATURE09197
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.1 Å)
Structure validation

226707

건을2024-10-30부터공개중

PDB statisticsPDBj update infoContact PDBjnumon